online pharmacy, prescription drugs online



Drugs online research references









  • Combination Therapy with an HMG-CoA Reductase Inhibitor and a Fibric Acid Derivative : A Critical Review of Potential Benefits and Drawbacks.
  • Serum ferritin and ceruloplasmin as coronary risk factors.
  • APOA5 gene variants, lipoprotein particle distribution and progression of coronary heart disease: results from the LOCAT study.
  • Early detection of drug interactions utilizing a computerized drug prescription handling system-focus on cerivastatin-gemfibrozil.
  • Mode of action and adverse effects of lipid lowering drugs.
  • Postprandial lipemia in the non-insulin-dependent diabetes mellitus patient. Effect of gemfibrozil
  • Inhibition of acyl-CoA: cholesterol acyltransferase decreases apolipoprotein B-100-containing lipoprotein secretion from HepG2 cells.
  • The effect of renal function on the pharmacokinetics of gemfibrozil.
  • Determination of gemfibrozil in plasma by high performance liquid chromatography.
  • Observation on the short and long term response to anti-lipemic drugs in southern Thailand.
  • Selective modification of rat hepatic microsomal fatty acid chain elongation and desaturation by fibrates: relationship with peroxisome proliferation.
  • Binding of 111In-labeled LDL to platelets of normolipemic volunteers and patients with heterozygous familial hypercholesterolemia.
  • The direct effect of hepatic peroxisome proliferators on rat Leydig cell function in vitro.
  • Prescribed use of cholesterol-lowering drugs in the United States, 1978 through 1988.
  • Hypertriglyceridemia during long-term interferon-alpha therapy in a series of hematologic patients.
  • Effects of gemfibrozil and clofibric acid on the uptake of taurocholate by isolated rat hepatocytes.
  • QT dispersion as a risk factor for sudden cardiac death and fatal myocardial infarction in a coronary risk population.
  • The priming effect of gemfibrozil on reactive oxygen metabolism of phagocytic leucocytes. An intriguing side effect.
  • Production of small high-density lipoprotein particles after stimulation of in vivo lipolysis in hypertriglyceridemic individuals: studies before and after triglyceride-lowering therapy.
  • Human S mu binding protein-2 binds to the drug response element and transactivates the human apoA-I promoter: role of gemfibrozil.
  • Effects of gemfibrozil administration on very low density lipoprotein receptor mRNA levels in rabbits.
  • Effects of gemfibrozil on serum lipids.
  • Gemfibrozil modifies acyl composition of liver microsomal phospholipids from guinea-pigs without promoting peroxisomal proliferation.
  • Peroxisomal cholesterol synthesis in vivo: accumulation of 4-methyl intermediate sterols after aminotriazole inhibition of cholesterol synthesis.
  • Serum retinol levels throughout 2 years of cholesterol-lowering therapy.
  • An enzymatic explanation of the differential effects of oleate and gemfibrozil on cultured hepatocyte triacylglycerol and phosphatidylcholine biosynthesis and secretion.
  • Gemfibrozil in the treatment of hyperlipoproteinemias
  • Gemfibrozil in the treatment of lipid metabolism disorders
  • Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study. Implications for treatment.
  • Reactivity of gemfibrozil 1-o-beta-acyl glucuronide. Pharmacokinetics of covalently bound gemfibrozil-protein adducts in rats.
  • Increase in intracellular triglyceride synthesis induced by gemfibrozil.
  • Predictive value for coronary heart disease of baseline high-density and low-density lipoprotein cholesterol among Fredrickson type IIa subjects in the Helsinki Heart Study.
  • Method for determining whether the number of hepatocytes in rat liver is increased after treatment with the peroxisome proliferator gemfibrozil.
  • HDL metabolism in HDL deficiency associated with familial hypertriglyceridemia: effect of treatment with gemfibrozil.
  • Influence of fibric acid derivatives on intermediate filament proteins in myocardiocyte cultures.
  • Effect of three fibrate derivatives and of two HMG-CoA reductase inhibitors on plasma fibrinogen level in patients with primary hypercholesterolemia.
  • Serum lipoprotein lipids after gemfibrozil treatment.
  • Repeated blood donation effective in treating hyperlipidemia.
  • Gemfibrozil absorption and elimination in kidney and liver disease.
  • Side effects of fibrates (except liver and muscle)
  • Use of drug therapy in hyperlipidemia in patients after myocardial infarct in the Czech Republic
  • Promotion of extended-release niacin tablets at a Veterans Affairs medical center.
  • Different effects of fibrates on the microsomal fatty acid chain elongation and the acyl composition of phospholipids in guinea-pigs.
  • Studies on the mechanism of fibrate-inhibited expression of plasminogen activator inhibitor-1 in cultured hepatocytes from cynomolgus monkey.
  • Direct effects of gemfibrozil on the fibrinolytic system. Diminution of synthesis of plasminogen activator inhibitor type 1.
  • The effects of bile salts and lipids on the physicochemical behavior of gemfibrozil.
  • Effects of lovastatin and gemfibrozil on high-density lipoprotein subfraction density and composition in patients with familial hypercholesterolemia.
  • Lipid-regulating action of gemfibrozil in the stroke-prone spontaneously hypertensive rat.
  • The modification of hemoglobin affinity for oxygen and tumor radiosensitivity by antilipidemic drugs.
  • Lipoprotein profiling by high performance gel chromatography.
  • Distinct responses of mouse hepatic CYP enzymes to corn oil and peroxisome proliferators.
  • Treatment of severe hypertriglyceridemia lowers plasma viscosity.
  • Hyperlipidemia.
  • Treatment of type III hyperlipoproteinemia with gemfibrozil to retard progression of coronary artery disease.
  • Pharmacist management of a hyperlipidemia clinic.
  • Antibodies to prothrombin imply a risk of myocardial infarction in middle-aged men.
  • Compliance with medication in the Helsinki Heart Study.
  • Comparative studies on the influence of different fibrates on serum lipoproteins in endogenous hyperlipoproteinaemia.
  • Effect of gemfibrozil on lipids, apoproteins, and postheparin lipolytic activities in normolipidemic subjects.
  • Synthesis and hypolipidemic activity of 2-substituted isobutyric acid derivatives.
  • Gemfibrozil predictably lowers triglycerides but does not significantly change plasminogen activator inhibitor activity in hypertriglyceridemic patients with a history of thrombosis.
  • Relationship between plasma lipids and palmitoyl-CoA hydrolase and synthetase activities with peroxisomal proliferation in rats treated with fibrates.
  • Evaluation of drug usage and expenditure in a hospital diabetes clinic.
  • Light and electron microscopy of liver in hyperlipoproteinemic patients under long-term gemfibrozil treatment.
  • Anti-cardiolipin antibodies and risk of myocardial infarction in a prospective cohort of middle-aged men.
  • Effect of AY-25,712 and other lipid-lowering agents on liver catalase and liver carnitine acetyltransferase in rats.
  • Gemfibrozil in CAPD patients.
  • Evaluation of a rodent peroxisome proliferator in two species of freshwater fish: rainbow trout (Onchorynchus mykiss) and Japanese medaka (Oryzias latipes)
  • Effects of different phenotypes of hyperlipoproteinemia and of treatment with fibric acid derivatives on the rates of cholesterol 7 alpha-hydroxylation in humans.
  • Effects of gemfibrozil on plasma lipoprotein-apolipoprotein distribution and platelet reactivity in patients with hypertriglyceridemia.
  • Study of the hypolipidemic properties of pectin, garlic and ginseng in hypercholesterolemic rabbits.
  • Protein-DNA interactions at a drug-responsive element of the human apolipoprotein A-I gene.
  • Beware of Cloudy Serum.
  • Comparison of the effects of gemfibrozil and clofibric acid on peroxisomal enzymes and cholesterol synthesis of rat hepatocytes.
  • Long-term safety and efficacy of combination gemfibrozil and HMG-CoA reductase inhibitors for the treatment of mixed lipid disorders.
  • DNA polymorphisms of apolipoprotein B and AI/CIII genes and response to gemfibrozil treatment.
  • Effect of dietary lipid-lowering drugs upon plasma lipids and egg yolk cholesterol levels of laying hens.
  • Gemfibrozil stimulates apolipoprotein A-I synthesis and secretion by stabilization of mRNA transcripts in human hepatoblastoma cell line (Hep G2).
  • Gemfibrozil metabolite inhibits in vitro low-density lipoprotein (LDL) oxidation and diminishes cytotoxicity induced by oxidized LDL.
  • Gemfibrozil and its oxidative metabolites: quantification of aglycones, acyl glucuronides, and covalent adducts in samples from preclinical and clinical kinetic studies.
  • Effect of gemfibrozil on peripheral atherosclerosis and platelet activation in a pig model of hyperlipidemia.
  • Fibrate-induced increase in blood urea and creatinine: is gemfibrozil the only innocuous agent?
  • Stimulatory effect of clofibrate and gemfibrozil administration on the formation of fatty acid esters of estradiol by rat liver microsomes.
  • Evidence for significant differences in microsomal drug glucuronidation by canine and human liver and kidney.
  • Effect of glycine/citric acid on the dissolution stability of hard gelatin capsules.
  • Effects of peroxisome proliferators on antioxidant enzymes and antioxidant vitamins in rats and hamsters.
  • Dyslipidemia and atherosclerosis. A forecast of pharmaceutical approaches.
  • PPARalpha-dependent induction of liver microsomal esterification of estradiol and testosterone by a prototypical peroxisome proliferator.
  • Cholesterol-lowering drugs. Some drugs with demonstrated efficacy but different benefits in primary and secondary prevention.
  • Is the relationship between adipose tissue and waist girth altered by weight loss in obese men?
  • Fatal rhabdomyolysis caused by cerivastatin
  • Effect of trans-dehydrocrotonin, a 19-nor-clerodane diterpene from Croton cajucara on experimental hypertriglyceridaemia and hypercholesterolaemia induced by Triton WR 1339 (tyloxapol) in mice.
  • Rx drugs
  • High-density lipoprotein and coronary heart disease: lessons from recent intervention trials.
  • Effect of peroxisome proliferators on the methylation and protein level of the c-myc protooncogene in B6C3F1 mice liver.
  • Hepatic disposition of the acyl glucuronide1-O-gemfibrozil-beta-D-glucuronide: effects of dibromosulfophthalein on membrane transport and aglycone formation.
  • Differential effects of gemfibrozil on migration, proliferation and proteoglycan production in human vascular smooth muscle cells.
  • Effect of ciprofibrate on C-reactive protein and fibrinogen levels.
  • Post-heparin LPL and HL activities after two months' treatment with gemfibrozil. Study in 6 normolipemic volunteers
  • Effect of gemfibrozil on biliary lipid metabolism in normolipemic subjects.
  • Intercalation and controlled release of pharmaceutically active compounds from a layered double hydroxide.
  • Hepatomegaly is an early biomarker for hepatocarcinogenesis induced by peroxisome proliferators.
  • Gemfibrozil inhibits CYP2C8-mediated cerivastatin metabolism in human liver microsomes.
  • Gemfibrozil encapsulation and release from microspheres and macromolecular conjugates.
  • Influence of P-glycoprotein inhibitors on accumulation of macrolides in J774 murine macrophages.
  • Cell-specific toxicity of fibrates in human embryonal rhabdomyosarcoma cells.
  • Apolipoprotein E polymorphism influences the serum cholesterol response to dietary intervention.
  • Polarised transport of monocarboxylic acid type drugs across rat jejunum in vitro: the effect of mucolysis and ATP-depletion.
  • Prevalence of antilipemic drug use in Taiwan: analysis of a sampling cohort within the national health insurance.
  • Use of a quadrupole linear ion trap mass spectrometer in metabolite identification and bioanalysis.
  • Lecithin:cholesterol acyltransferase gene expression is regulated in a tissue-selective manner by fibrates.
  • Antibodies to human heat shock protein 60, hypertension and dyslipidemia. A study of joint effects on coronary risk.
  • Binding of 111In-labeled HDL to platelets from normolipemic volunteers and patients with heterozygous familial hypercholesterolemia.
  • Effects of baseline level of triglycerides on changes in lipid levels from combined fluvastatin + fibrate (bezafibrate, fenofibrate, or gemfibrozil).
  • Inhibition of endothelial cell expression of plasminogen activator inhibitor type-1 by gemfibrozil.
  • Lack of hypotriglyceridemic effect of gemfibrozil as a consequence of age-related changes in rat liver PPARalpha.
  • Fibrates modify the expression of key factors involved in bile-acid synthesis and biliary-lipid secretion in gallstone patients.
  • LDL physical and chemical properties in familial combined hyperlipidemia.







    online pharmacies || Hair Million herbal formula for hair loss and hair growth || Amoxicillin || Tramadol || Paxil || Rx Drugs USA, Prescription Drugs Online Pharmacy || Zithromax || online pharmacy || Antibiotics and prescription medications online literature || Antibiotics